D3 (Drug Discovery and Development), A*Star, Singapore
The era of a “one-size-fits-all” approach to patient treatment & drug development is over. Instead the mantra of delivering the right drug to the right patient at the right time – the very essence of personalised medicine – is taking over. The reason is simple, rapid technological advances in sequencing technology, the increase in computer power and algorithms to manage big data, the advent of artificial intelligence plus wide-spread public investment to support these advances means that precision medicine is rapidly realizing its potential of delivering superior outcomes for patients around the world
This year’s congress draws on a truly international panel to examine the advances in technology and the latest applications that will deliver the medicines of tomorrow.
Chairman Bio-Ethics Committee Center of Excellence in Genomic Medicine Research, Saudi Arabia
Director of Bioinformatics Core Institute of Health Science, Chinese Academy of Sciences, China
Director – Computational Biology and Bioinformatics Pfizer Worldwide Research & Development, US
Join this meeting and be part of an environment bringing together a multi-disciplined community who share one aim – developing ground breaking and impactful treatments for patients.
Presentation by Lon Cardon, Senior Vice President, Target Sciences, GlaxoSmithKline